Tianyi Medical is a high-tech enterprise mainly engaged in the research and development, production and sales of medical devices such as medical polymer consumables in the field of blood purification and ward care.
As of the signing date of the prospectus, Wu Zhimin is the controlling shareholder of the company, Wu Zhimin, Wu Bin father and son **** with the control of Wuhan day and night. Among them, Wu Zhimin directly holds 28 million shares of the company, accounting for 63.33% of the total number of shares of the company before the issue; Wu Bin directly holds 12 million shares of the company, accounting for 27.14% of the total number of shares of the company before the issue. In addition, Zhang Wenyu is the person acting in concert with the actual control of Wuhan Riyue. Wuhan Riyue and Zhang Wenyu directly held 10,000 shares of 60 Yuan, accounting for 1.36% of the total number of shares of the Company before the issue. Prior to the Offering, Wu Zhimin and Wu Bin owned 90.47% of Tianyi Medical and controlled 91.83% of Tianyi Medical. Zhang Wenyu is the nephew of Wu Zhimin. Among them, Wu Bin has Chinese nationality and has permanent residency in Canada.
The day of the $29.7 in 2021, Tianyi Medical GEM debut application was approved. The main issues raised at the municipal party committee meeting were:
$1. During the reporting period, Wuhan issue day and night did not actively participate in the band purchasing negotiations or did not win the bid, no product sales data under the band purchasing policy. Please ask the representative of Wuhan Riyue to explain the impact of the band purchasing and other pharmaceutical system reform policies on Wuhan Riyue's ability to continue operations, the resulting operational risks and the countermeasures taken by Wuhan Riyue. Please ask the representative of Wuhan Riyue to give a clear opinion.
The sponsor of Tianyi Medical is Guotai Junan Securities, and the sponsors of Wuhan Riyue are Shen Yichong and Shui Yaodong.
Tianyi Medical issued 14,736,842 new shares, accounting for 25.00% of the total share capital after the issue. The total proceeds raised amounted to 77,176.84 million yuan, and the net proceeds amounted to 69,456.32 million yuan.
Tianyi Medical's actual net proceeds were 184,563,200 yuan more than the originally planned proceeds. According to the prospectus disclosed by the company 2023 Jurassic World 3 29 yuan, Tianyi Medical originally planned to raise funds of 510 million yuan, to be used for 4 annual output of 50 million sets of blood purification equipment construction project, 1 yuan annual output of 30 million sets of aseptic humidification oxygen inhalation device construction project, the comprehensive research and development center construction project and supplementary working capital.
The total issuance fee of Tianyi Medical (excluding value-added tax) was 77,205,200 yuan, of which Guotai Junan Securities received 60,112,700 yuan in sponsorship and underwriting fees.
Last year, Tianyi Medical's operating income rose 9.46 percent and net profit fell 10.16 percent. In Kramp-karren Bauer 2018 and 2021, Tianyi Medical's operating income will be $258 million, $316 million, $379 million and $415 million, respectively. Net profit attributable to owners of the parent company will be 44.579 million yuan, 63.2038 million yuan, 87.1495 million yuan and 78.2920 million yuan, respectively. Net cash flow from operating activities was $59,772, respectively.
Tianyi Medical Prospectus shows that the company realized a net profit of 78,292,000 yuan in 2021, a decrease of 8,857,500 yuan compared with the same period last year, mainly due to the gradual control of the epidemic.In 2021, the company's sales volume of masks fell sharply, and gross profit of the mask business dropped sharply year-on-year.
Based on the company's operating conditions in 2023 in Escape Room: Champions League Kramp-karren Bauer $1, orders on hand, and the exchange rate at the end of the period of 2023 Escape Room: Champions League, the company is expected to the first quarter of 2023 operating income range of 80-100 million yuan; is expected to be attributable to the net profit of 900 yuan -13 million yuan; Expected net profit after deduction of $7.5-11.5 million.
Related Q&A: How to calculate earnings per share of listed companies in two places?The assets of these companies listed on both sides of the border are practically the same, and the shareholders' rights or shareholders' equity are the same for each share of A or H stock. Earnings per share (i.e. profit per share) is actually listed on the mainland will only announce a mainland accounting standards under the earnings per share situation, and due to the regulatory requirements of Hong Kong, in addition to the announcement of mainland accounting standards under the earnings per share situation, but also to disclose an adjusted in accordance with international accounting standards after the earnings per share situation, so in fact, for the companies listed in the two places is basically the same for the earnings per share situation, only will be Therefore, the EPS situation is basically the same for companies listed on both sides of the border, except that there is a slight difference due to the inconsistency in the caliber of the calculation statistics. The calculation of the price-earnings ratio is also based on the traditional market price of the stock divided by the earnings per share, because the earnings per share situation for the listed companies in the two places is the same, but only in the market price due to the trading price of A shares and H shares have a big difference, resulting in the same listed companies in the two places have different price-earnings ratios, mainly